HEALTH OF WOMAN. 2015.8(104):176–179; doi 10.15574/HW.2015.104.176 

Clinical features of malignant process and biomarkers of high risk of relapse in patients with breast cancer 

Zhylchuk A. V., Semesyuk N. I., Kudryavets Yu. I.

Regional oncologic dispensary, Rivne

Institute of experimental pathology, Oncology and radiobiology R.E Kavetsky, Kiev 

Today, along with standard prognostic and predicative factors in breast cancer the most promising in the clinic is the so-called minimally invasive «liquid biopsy», which includes the identification of disseminated tumor cells and micrometastases in the bone marrow of patients and determination of cytokine profile in the bone marrow and the blood of patients has before the start of their treatment. Based on this ideology, studied 33 patients with breast cancer in stage T1-4N0-2M0-1 that based on the presence or absence of progression of malignancy were divided into 2 groups: 14 in remission that 19 – in the stage of progression. Tumor cells in cytospin preparations of bone marrow mononuclear cells revealed immunocytochemical method using antibodies to pancytokeratine, cytokine levels in the plasma was determined by their biological activity (TNF, M-CSF, IFN) or by ELISA (IL-1, IL-6, TGF-b, VEGF).

It is shown that the presence of disseminated tumor cells in the bone marrow and the high level of TNF and M-CSF activity in bone marrow and the blood of breast cancer patients indicates higher risk (P<0,001) of recurrence of the malignant process. 

Key words: breast cancer, disseminated tumor cells, cytokine. 

REFERENCES

1. Лекции по фундаментальной и клинической онкологии под редакцией ВМ Моисеенка, АФ Урманцевой, КП Хансона. Издательство Н-Л. 2004:703.

2. Лекарственная терапия рака молочной железы: Под ред. НИ Переводчиковой и МБ Стениной. М, Практика. 2014:284.

3. Мерабишвили ВМ. 2013. Эпидемиология и выживаемость больных раком молочной железы. Вопросы онкологии 59;3:314–319.

4. Miller AB, Wall C, Baines CJ. 2014. Twenty five year follow up breast cancer incidence and mortality of the Canadian Breast Screaning Study: Randomized Screening trial. BMJ. 348:366. http://dx.doi.org/10.1136/bmj.g366; PMid:24519768 PMCid:PMC3921437

5. Toriola AT, Colditz JA. 2013. Trends in breast cancer incidence and mortality in the United States: implication for prevention. Breast cancer Res Trial. 138:665–673. http://dx.doi.org/10.1007/s10549-013-2500-7; PMid:23546552

6. Pantel K, Schlimok G, Braun S et al. 1993. Differential eхpression of proliferation- associated molecules in individual micormetastatic carcinoma cells. J Natl Cancer Inst, 85:1419–24. http://dx.doi.org/10.1093/jnci/85.17.1419; PMid:7688814

7. Janni W, Gastroph S, Hepp F, Kentenich C, Rjosk D, Schindlbeck C, Dimpfl T, Sommer H, Braun S. 2000, May 15. Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma. Cancer. 88(10):2252–9. http://dx.doi.org/10.1002/(SICI)1097-0142(20000515)88:10<2252::AID-CNCR8>3.0.CO;2-Q

8. Stephan Braun, MD, Florian D Vogl, MD, Bjшrn Naume, MD, Wolfgang Janni, MD. A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer.

9. Logan TF, Gooding WE, Whiteside TL et al. 1997. Biologic response modulation by TNF-1 in a phase 1b trial in cancer patients. J. of Immunotherapy 20:387–398. http://dx.doi.org/10.1097/00002371-199709000-00008

10. Wu S, Bozer CM, Whitaker RS et al. 1993. Tumor necrosis factor as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor expression. Cancer Res. 53:1939–1944. PMid:8385577

11. Матяш МГ, Хричнокова ТЮ, Шаталова ВН, Гольберг ВЕ. 2006. Злокачественные опухоли, продуцирующие гранулоцитраный колониестимулирующий фактор. Сибирский онкологический журнал 2(18): 68–70.

12. Sato Y, Takahashi Y, Nishie K et al. 2005. A case of granulocyte-colony stimulating factor producing smale cell carcinoma of esophagus. Nippon Shokakibyo Gakkai Zosshi. 102:888–893. PMid:16038435

13. Mikam M, Tanaka K, Komiyama S et ac. 2005. Primary serosus carcinoma of the peritoneum producing granulocyte colony-stimulating factor. Aeta Obster Gynecol. Scand. 84;8:820–822. http://dx.doi.org/10.1111/j.0001-6349.2005.0498b.x; PMid:16026414

14. Ikaeda T, Ohgaki K, Miura M et al. 2005. Granulocyte colony stimulating factor-producing gallbladder cancer without recurrence more than 2 years after resection: report of a case. Surg. Today 35;7:590–593. http://dx.doi.org/10.1007/s00595-004-2981-4; PMid:15976958

15. Terao S, Yamada Y et ac. 2005. Granulocyte-colony stimulating factor producing urothelial carcinoma of renal pelvis. Int. J. Urol. 12;5:500–502. http://dx.doi.org/10.1111/j.1442-2042.2005.01084.x; PMid:15948753